Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer
NCT ID: NCT00899210
Last Updated: 2011-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial is studying matrix metalloproteinases after surgery or radiofrequency ablation in patients with liver metastases from colorectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
NCT00002997
Independent Risk Factors Analysis and Model Construction For Recurrence After Radiofrequency/Microwave Ablation of Colorectal Cancer With Liver Metastases: a Retrospective, Multicenter Trial
NCT05268549
Ablation vs Resection of Colorectal Cancer Liver Metastases
NCT05129787
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
NCT01565811
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
NCT04798898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Describe the kinetics of postoperative changes of serum matrix metalloproteinases (MMP) (MMP-1, MMP-2, MMP-7, MMP-9) and their inhibitors (TIMP) (TIMP-1, TIMP-2) as a function of surgical technique.
Secondary
* Determine the predictive value of postoperative risk of recurrence.
* Correlate the risk of recurrence with surgical technique.
* Determine whether elevated serum levels of MMP are a better marker than the carcinoembryonic antigen of hepatic or extrahepatic recurrence.
* Determine whether the postoperative serum of HGF/SF is correlated to changes in plasma levels of MMPs.
OUTLINE: Blood samples are collected periodically before and after treatment to analyze for metalloproteinases and their inhibitors.
After completion of study treatment, patients are followed at day 45 and then every 3 months for 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory biomarker analysis
cryosurgery
radiofrequency ablation
therapeutic conventional surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets 1 of the following criteria:
* Patients with histologically confirmed adenocarcinoma of the colon or rectum and liver metastases
* Must have undergone prior complete resection of the tumor more than 3 months ago
* Liver metastases must be resectable or accessible for radiofrequency ablation
* Patients undergoing cryosurgery of the digestive tract for a reason other than cancer or infection (control)
PATIENT CHARACTERISTICS:
* No other neoplastic disease that is measurable or being treated other than colorectal cancer
* No heart failure or severe respiratory disease
* No uncontrolled infection or other severe disease
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No participation in another study involving new drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine Rebischung
Role: STUDY_CHAIR
University Hospital, Grenoble
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUG-METALLO-1
Identifier Type: -
Identifier Source: secondary_id
RECF0455
Identifier Type: -
Identifier Source: secondary_id
CDR0000574192
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.